Luye Pharma Group (SHSC:2186) Stock Valuation, Peer Comparison & Price Targets

Share Price vs Fair Value

What is the Fair Price of 2186 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2186's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2186's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2186?

Key metric: As 2186 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2186. This is calculated by dividing 2186's market cap by their current earnings.
What is 2186's PE Ratio?
PE Ratio	11.6x
Earnings	CN¥770.46m
Market Cap	CN¥8.93b

2186 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	6.6x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does 2186's PE Ratio compare to its peers?

The above table shows the PE ratio for 2186 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	8.7x
719 Shandong Xinhua Pharmaceutical	8x	n/a	HK$9.8b
2005 SSY Group	8.1x	5.8%	HK$11.3b
570 China Traditional Chinese Medicine Holdings	11.1x	n/a	HK$11.4b
1681 Consun Pharmaceutical Group	7.6x	14.9%	HK$7.0b
2186 Luye Pharma Group	11.6x	16.9%	HK$9.6b

Price-To-Earnings vs Peers: 2186 is expensive based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (8.7x).

Price to Earnings Ratio vs Industry

How does 2186's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 2186 is expensive based on its Price-To-Earnings Ratio (11.6x) compared to the Hong Kong Pharmaceuticals industry average (8.3x).

Price to Earnings Ratio vs Fair Ratio

What is 2186's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2186 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11.6x
Fair PE Ratio	12.1x

Price-To-Earnings vs Fair Ratio: 2186 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the estimated Fair Price-To-Earnings Ratio (12.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2186 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	HK$2.55	HK$3.64 +42.8%	12.5%	HK$3.97	HK$3.00	n/a	3
Nov ’25	HK$2.83	HK$3.64 +28.7%	12.5%	HK$3.97	HK$3.00	n/a	3
Oct ’25	HK$3.35	HK$3.59 +7.1%	15.5%	HK$3.99	HK$2.80	n/a	3
Sep ’25	HK$3.05	HK$3.63 +19.0%	15.1%	HK$4.03	HK$2.85	n/a	3
Aug ’25	HK$2.81	HK$3.05 +8.4%	21.7%	HK$3.95	HK$2.39	n/a	3
Jul ’25	HK$2.70	HK$3.05 +12.8%	21.4%	HK$3.94	HK$2.40	n/a	3
Jun ’25	HK$2.68	HK$3.05 +13.6%	21.4%	HK$3.94	HK$2.40	n/a	3
May ’25	HK$2.77	HK$3.01 +8.7%	22.3%	HK$3.95	HK$2.40	n/a	3
Apr ’25	HK$2.73	HK$3.49 +27.8%	29.4%	HK$4.94	HK$2.37	n/a	4
Mar ’25	HK$2.90	HK$3.44 +18.8%	29.3%	HK$4.97	HK$2.38	n/a	4
Feb ’25	HK$2.62	HK$3.40 +29.8%	30.7%	HK$4.97	HK$2.39	n/a	4
Jan ’25	HK$3.73	HK$2.90 -22.3%	20.8%	HK$3.75	HK$2.40	n/a	3
Dec ’24	HK$3.87	HK$2.90 -25.1%	20.8%	HK$3.75	HK$2.40	n/a	3
Nov ’24	HK$3.80	HK$2.91 -23.5%	18.7%	HK$3.65	HK$2.37	HK$2.83	3
Oct ’24	HK$3.51	HK$2.89 -17.7%	19.1%	HK$3.65	HK$2.37	HK$3.35	3
Sep ’24	HK$2.88	HK$3.12 +8.2%	19.8%	HK$3.86	HK$2.38	HK$3.05	4
Aug ’24	HK$3.59	HK$3.48 -2.9%	31.2%	HK$5.17	HK$2.40	HK$2.81	4
Jul ’24	HK$3.31	HK$3.28 -0.8%	37.9%	HK$5.15	HK$2.05	HK$2.70	4
Jun ’24	HK$3.44	HK$3.48 +1.1%	33.6%	HK$5.41	HK$2.15	HK$2.68	5
May ’24	HK$3.85	HK$3.50 -9.2%	33.7%	HK$5.45	HK$2.15	HK$2.77	5
Apr ’24	HK$3.64	HK$3.25 -10.6%	41.2%	HK$5.50	HK$2.00	HK$2.73	5
Mar ’24	HK$3.69	HK$3.25 -11.8%	41.2%	HK$5.50	HK$2.00	HK$2.90	5
Feb ’24	HK$4.11	HK$3.25 -20.8%	41.2%	HK$5.50	HK$2.00	HK$2.62	5
Jan ’24	HK$3.66	HK$2.96 -19.2%	46.8%	HK$5.57	HK$2.00	HK$3.73	5
Dec ’23	HK$3.09	HK$2.23 -27.9%	22.2%	HK$3.08	HK$1.92	HK$3.87	4
Nov ’23	HK$1.97	HK$2.40 +21.7%	23.5%	HK$3.10	HK$1.92	HK$3.80	5

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Consun Pharmaceutical Group

HK$7.0b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

1681

HK$8.22

7D

-2.1%

1Y

74.9%

Innovent Biologics

HK$63.1b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$37.00

7D

-0.5%

1Y

-15.4%

3SBio

HK$13.4b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.52

7D

-4.3%

1Y

-26.2%

Luye Pharma Group Valuation